7 Oversold European Stocks to Buy

Page 2 of 2

6. Alvotech (NASDAQ:ALVO)

Alvotech (NASDAQ:ALVO) ranks among the oversold European stocks to buy. On March 19, Alvotech (NASDAQ:ALVO) revealed its full-year and Q4 2025 earnings results, delivering revenues of $593 million for the year, representing a 21% year-over-year growth and greatly surpassing analyst projections with Q4 EPS of $0.03 versus a predicted loss of $0.0833.

Alvotech (NASDAQ:ALVO) has revealed 15 distinct programs aimed at key biologics, such as Xolair, Entyvio, Eylea HD, and Keytruda, with over 30 biosimilar candidates in development. For these reported candidates, the total addressable market is more than $185 billion.

Despite barriers to regulation in the US, Alvotech’s on-market products have managed to gain traction in overseas markets. The company’s biosimilar of Humira, AVT02, profited from the originator’s dwindling US market share, which declined from 70% to around 45% by the end of 2025.

On the manufacturing side, Alvotech (NASDAQ:ALVO) is extending its perfusion manufacturing capacity in Reykjavik by adding a third medical component and an additional product production unit.

​Alvotech (NASDAQ:ALVO) is a biotechnology company specializing in the development, manufacturing, and commercialization of biosimilar medicines to provide affordable biologic alternatives globally.

While we acknowledge the potential of ALVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALVO and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Oversold European Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

Page 2 of 2